Background: Behçet's disease is a chronic, relapsing, systemic vasculitis, characterized by diverse spectrum of clinical presentation, variable severity and can potentially involve any organ [1]. Several biomarkers were used for monitoring BD's have been explored, yet the results were conflicting and inconclusive [2]. Objectives: This study aimed at assessing the usefulness of calprotectin and Ischaemia Modified Albumin (IMA) serum concentrations to measure disease activity in BD. Methods: Cross sectional study conducted on sixty BD cases and 60 age- and gender-matched subjects as controls. BD activity was assessed with BDCAF which assess clinical characteristics present during the previous one month before evaluation. The total BDCAF score was calculated by adding up the positive components (maximum score = 12). A BDCAF patient index score ≥2 was considered as active BD, while a score less than 2 was considered as inactive BD. Serum calprotectin concentrations were quantified by ELISA. Levels of CRP and high-sensitivity CRP (hsCRP) and albumin were detected using the immunoturbidimetric technique. The limit of detection for hsCRP was 0.02 mg/l while for calprotectin, it was 1.6 ng/ml. IMA was quantified based on albumin cobalt binding colorimetric assay and the levels were expressed in absorbance units (ABSU). To obtain corrected IMA values, the equation (individual albumin level/median albumin level of population) × IMA ABSU value was applied. Results: The active BD cases had significantly greater IMA serum level than inactive BD cases (p=0.013) and than controls (p<0.001). In addition, the inactive BD group had significantly higher IMA serum level than controls (p<0.001). The serum calprotectin levels in active and inactive BD groups were significantly greater compared to measured in controls (p<0.001). On the other hand, the difference in serum calprotectin concentration was insignificant between the active and inactive BD patients. Binary logistic regression analysis revealed that hs-CRP and IMA serum levels are the strongest predictors for the activity of the active BD (p=0.011, and 0.005 respectively). ROC curve analysis for the ability of IMA serum level for discrimination between active and inactive BD groups revealed an AUC = 0.738. Conclusion: Serum calprotectin and IMA concentrations were significantly elevated in BD. IMA was significantly greater among active BD cases in comparison to inactive BD cases indicating its potential importance as a new marker of activity in BD. REFERENCES: [1] Nair JR, Moots RJ. Behcet's disease. Clin Med (Lond). 2017 Feb;17(1):71-77. [2] Masoumi M, Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, et al. The value of ESR, CRP, and the Iran Behcet's Disease Dynamic Activity Measure (IBDDAM) in differentiating the active or inactive phases for the manifestations of Behcet's disease. J Orthop Rheumatol. 2018;4(1). Acknowledgements: The authors acknowledge RA cases that gave consent and agreed to participate. Disclosure of Interests: None declared.
No takes yet. Share an insight, caveat, or question.
Hussein et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: